Immunovant CTO Jay Stout sells $75,099 in shares

Jay S. Stout, Chief Technology Officer at Immunovant, Inc. (NASDAQ:IMVT), sold 2,595 shares of the company’s common stock on October 21, 2026. The shares were sold at a weighted average price of $28.94, with individual transaction prices ranging from $28.31 to $29.15 per share, totaling $75,099. The stock currently trades at $28.41, reflecting a strong 50% gain over the past year.

The transaction was identified as a "sell to cover" sale, executed to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs). These RSUs, totaling 100,000, were granted on April 17, 2023, with 6,250 of them vesting on October 17, 2026. This sale was mandated by Immunovant’s policy requiring tax withholding obligations to be funded through such transactions and does not represent a discretionary sale by Mr. Stout.

Following this transaction, Mr. Stout directly beneficially owns 198,937 shares of Immunovant common stock. The biotechnology company, valued at $6 billion, holds more cash than debt on its balance sheet according to InvestingPro analysis, which also indicates the stock is currently overvalued relative to its Fair Value. Investors can access 8 additional ProTips and comprehensive financial metrics on the platform.

In other recent news, Immunovant has announced that its drug candidate, IMVT-1402, failed to meet the primary endpoint in a clinical trial for cutaneous lupus erythematosus. As a result, the company has decided to discontinue the development of the drug for this indication. Despite this setback, H.C. Wainwright has maintained a Buy rating for Immunovant, with a price target of $41.00. Meanwhile, Cantor Fitzgerald has reiterated an Overweight rating on Immunovant shares following the company’s first-quarter earnings report, indicating continued confidence in the company’s prospects.

In related developments, Roivant Sciences, which has ties to Immunovant, reported a wider-than-expected first-quarter loss. The company posted an earnings per share of -$0.75, missing analysts’ forecast of -$0.60. This miss is attributed to increased spending on research and development as Roivant prepares for a busy second half of 2026. Investors received limited near-term revenue details, reflecting the company’s focus on long-term pipeline development.